Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Current Assets (2018 - 2025)

Bicycle Therapeutics' Current Assets history spans 8 years, with the latest figure at $682.9 million for Q4 2025.

  • For Q4 2025, Current Assets fell 26.46% year-over-year to $682.9 million; the TTM value through Dec 2025 reached $682.9 million, down 26.46%, while the annual FY2025 figure was $682.9 million, 26.46% down from the prior year.
  • Current Assets reached $682.9 million in Q4 2025 per BCYC's latest filing, down from $738.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.0 billion in Q2 2024 to a low of $215.4 million in Q1 2021.
  • Average Current Assets over 5 years is $561.5 million, with a median of $487.3 million recorded in 2021.
  • Peak YoY movement for Current Assets: soared 194.47% in 2021, then dropped 26.46% in 2025.
  • A 5-year view of Current Assets shows it stood at $458.6 million in 2021, then fell by 19.45% to $369.4 million in 2022, then skyrocketed by 52.11% to $561.9 million in 2023, then soared by 65.27% to $928.6 million in 2024, then fell by 26.46% to $682.9 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Current Assets are $682.9 million (Q4 2025), $738.8 million (Q3 2025), and $804.3 million (Q2 2025).